New Anticoagulants: Anti-IIa or Anti-Xa Agents?

  • C. M. Samama


The iatrogenicity of vitamin K antagonists is well established. Each year in France, vitamin K antagonists account for more than 17,000 hospital admissions and nearly 4000 deaths. Alternative treatment would be more than welcome. It is hard to imagine a drug that would induce more complications than a vitamin K antagonist.


Deep Vein Thrombosis Dabigatran Etexilate Enoxaparin Group Rivaroxaban Group Oral Thrombin Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bauer KA (2001) Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 58 (Suppl 2):S14–17Google Scholar
  2. 2.
    Turpie AG, Gallus AS, Hoek JA (2001) A synthetic pentasaccharide for the prevention of deepvein thrombosis after total hip replacement. N Engl J Med 344: 619–625CrossRefPubMedGoogle Scholar
  3. 3.
    Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162: 1833–1840CrossRefPubMedGoogle Scholar
  4. 4.
    Büller HR, Davidson BL, Decousus H, et al (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349: 1695–1702CrossRefPubMedGoogle Scholar
  5. 5.
    Büller HR, Davidson BL, Decousus H, et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140: 867–873PubMedGoogle Scholar
  6. 6.
    Mehta SR, Granger CB, Eikelboom JW, et al (2007) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 50: 1742–1751CrossRefPubMedGoogle Scholar
  7. 7.
    Warkentin TE, Maurer BT, Aster RH (2007) Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 356: 2653–2655CrossRefPubMedGoogle Scholar
  8. 8.
    Buller HR, Cohen AT, Davidson B, et al (2007) Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357: 1094–1104CrossRefPubMedGoogle Scholar
  9. 9.
    Buller HR, Cohen AT, Davidson B, et al (2007) Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357: 1105–1112CrossRefPubMedGoogle Scholar
  10. 10.
    Bousser MG, Bouthier J, Buller HR, et al (2008) Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371: 315–321CrossRefPubMedGoogle Scholar
  11. 11.
    Weitz JI, Hirsh J, Samama MM (2004) New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:265S–286SCrossRefPubMedGoogle Scholar
  12. 12.
    Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005;3: 1843–53CrossRefPubMedGoogle Scholar
  13. 13.
    Eriksson BI, Borris LC, Dahl OE, et al (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114: 2374–2381CrossRefPubMedGoogle Scholar
  14. 14.
    Lassen MR, Ageno W, Borris LC, et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358: 2776–2786CrossRefPubMedGoogle Scholar
  15. 15.
    Eriksson BI, Borris LC, Friedman RJ, et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358: 2765–2775CrossRefPubMedGoogle Scholar
  16. 16.
    Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5: 2368–2375CrossRefPubMedGoogle Scholar
  17. 17.
    Weitz JI (2007) Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 5 (Suppl 1): 65–67CrossRefPubMedGoogle Scholar
  18. 18.
    Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3: 103–111CrossRefPubMedGoogle Scholar
  19. 19.
    Eriksson B, Dahl O, Rosencher N, et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized study. J Thromb Haemost 5: 2178–2185CrossRefPubMedGoogle Scholar
  20. 20.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370: 949–956CrossRefPubMedGoogle Scholar
  21. 21.
    The RE-MOBILIZE Writing Committee (2009) Oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24: 1–9Google Scholar
  22. 22.
    Gross PL, Weitz JI (2008) New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 28: 380–386CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • C. M. Samama
    • 1
  1. 1.Department of Anesthesiology and Intensive CareHotel-Dieu University HospitalParis Cedex 04France

Personalised recommendations